Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on April 15, 2026. Live audio and a replay (available for two weeks) can be accessed via the company events page.

Pacira also granted inducement equity awards on April 2, 2026: stock options aggregating 5,000 shares (10-year term, exercise price $22.70, four-year vesting) and restricted stock units aggregating 13,000 shares (four annual vesting installments beginning April 1, 2027). Awards were approved by the People & Compensation Committee under Nasdaq Rule 5635(c)(4).

AI-generated analysis. Not financial advice.

News Market Reaction – PCRX

+3.20%

1 alert

+3.20% News Effect

On the day this news was published, PCRX gained 3.20%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Stock options granted: 5,000 shares RSUs granted: 13,000 shares Option term: 10 years +5 more

8 metrics

Stock options granted 5,000 shares Inducement awards to two employees under 2014 Inducement Plan on Apr 2, 2026

RSUs granted 13,000 shares Inducement RSU awards to seven employees on Apr 2, 2026

Option term 10 years Term of inducement stock options granted under Inducement Plan

Vesting period 4 years Vesting schedule for inducement stock options and RSUs

Initial vesting tranche 25 percent Portion of option shares vesting on first anniversary of employment

Subsequent vesting 36 months Equal quarterly option vesting over 36 months after first anniversary

Exercise price $22.70 per share Closing PCRX price on Nasdaq Global Select Market on grant date

Fireside chat time 9:30 AM ET Needham Virtual Healthcare Conference on April 15, 2026

Market Reality Check

Price: $23.00 Vol: Volume 397,733 is below t...

low vol

$23.00 Last Close

Volume Volume 397,733 is below the 20-day average of 732,501, suggesting limited trading interest ahead of this update. low

Technical Shares at $22.53 are trading below the 200-day MA of $23.54 and 18.49% under the 52-week high.

Peers on Argus

PCRX was up 1.17% with modestly positive moves in peers like COLL (+1.2%) and HR...

1 Up

PCRX was up 1.17% with modestly positive moves in peers like COLL (+1.2%) and HROW (+1.16%), but scanner data shows only 1 peer in momentum and no broad sector push.

Common Catalyst Both PCRX and COLL disclosed participation in investor conferences, pointing to an investor-relations focused news day rather than a sector-wide clinical or regulatory catalyst.

Historical Context

5 past events · Latest: Mar 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 30	Clinical data update	Positive	+1.7%	Real-world EXPAREL data showed reduced cost of care versus comparators.
Mar 12	Activist nomination	Neutral	+3.1%	DOMA Perpetual nominated three director candidates for Pacira’s board.
Mar 11	Strategy & metrics	Positive	+3.1%	Company reaffirmed shareholder value focus and highlighted 2025 operational metrics.
Mar 11	Activist nomination	Neutral	+1.7%	Additional coverage of DOMA’s three director nominations and campaign.
Mar 06	Inducement grants	Neutral	-3.8%	Reported Nasdaq Rule 5635(c)(4) inducement equity awards to new employees.

Pattern Detected

Clinical/data and shareholder-value messaging have coincided with positive moves, while routine inducement grant disclosures previously saw a -3.76% reaction.

Recent Company History

Recent PCRX news has mixed strategic, clinical, and governance themes. In March 2026, real-world EXPAREL data showing lower costs coincided with a +1.7% move. Activist-related headlines from DOMA and the company’s response, highlighting its 5x30 strategy and 2025 metrics, were followed by gains of up to +3.07%. By contrast, a prior Nasdaq Rule 5635(c)(4) inducement grant disclosure on Mar 6, 2026 saw shares down -3.76%, framing today’s similar grant announcement in a known context.

Market Pulse Summary

This announcement combines a routine investor-relations event with inducement equity grants under Na...

Analysis

This announcement combines a routine investor-relations event with inducement equity grants under Nasdaq Listing Rule 5635(c)(4). It follows a March 2026 inducement disclosure that coincided with a -3.76% move, contrasting with positive reactions of up to +3.07% on clinical and strategic news. Investors reviewing this update may focus on how incremental dilution from 5,000 options and 13,000 RSUs fits alongside ongoing activist engagement, insider transactions, and Pacira’s broader 5x30 strategy.

Key Terms

nasdaq listing rule 5635(c)(4), inducement awards, stock options, restricted stock units, +4 more

8 terms

nasdaq listing rule 5635(c)(4) regulatory

"Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Pacira today announced..."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement awards financial

"Pacira today announced the granting of inducement awards on April 2, 2026..."

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

stock options financial

"Two employees received stock options to purchase an aggregate of 5,000 shares..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

restricted stock units financial

"seven employees received restricted stock units for an aggregate of 13,000 shares..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting schedule financial

"The stock options have a 10-year term and a four-year vesting schedule..."

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

exercise price financial

"The stock options have an exercise price of $22.70 per share..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

nasdaq global select market regulatory

"the closing trading price of Pacira common stock on the Nasdaq Global Select Market..."

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

restricted stock unit financial

"Each restricted stock unit represents the contingent right to receive one share..."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 25^th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on Wednesday, April 15, 2026.

Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira today announced the granting of inducement awards on April 2, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Two employees received stock options to purchase an aggregate of 5,000 shares of Pacira common stock and seven employees received restricted stock units for an aggregate of 13,000 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $22.70 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on April 1, 2027.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com

FAQ

When will Pacira (PCRX) present at the Needham Virtual Healthcare Conference on April 15, 2026?

Pacira will present at 9:30 AM ET on April 15, 2026. According to the company, live audio will stream on its investor events page and a replay will be available for two weeks following the event.

How can investors access Pacira (PCRX) live audio and replay for the April 15, 2026 presentation?

Investors can access live audio and a replay via the company’s investor events page. According to the company, the replay will remain available for two weeks after the April 15, 2026 presentation.

What inducement equity awards did Pacira (PCRX) grant on April 2, 2026?

Pacira granted stock options totaling 5,000 shares and restricted stock units totaling 13,000 shares. According to the company, these awards were made as inducements under its Amended and Restated 2014 Inducement Plan.

What are the key terms of the stock options Pacira (PCRX) granted on April 2, 2026?

The stock options have a 10-year term and a four-year vesting schedule with 25% vesting after one year. According to the company, the exercise price is $22.70, the closing Nasdaq price on the grant date.

When do the restricted stock units for Pacira (PCRX) awards vest and what do they represent?

Each restricted stock unit represents the right to one share and vests in four annual installments starting April 1, 2027. According to the company, vesting is subject to continued employment and award agreement terms.

Were Pacira (PCRX) inducement awards approved by shareholders for the April 2, 2026 grants?

No, the awards were approved by the People & Compensation Committee without shareholder approval under Nasdaq Listing Rule 5635(c)(4). According to the company, the committee approved the inducement awards as permitted by Nasdaq rules.